Workflow
PHA
icon
Search documents
Century Lithium powers LFP batteries with pure lithium carbonate – ICYMI
Proactiveinvestors NA· 2025-07-12 15:05
Century Lithium Corp. (TSX-V:LCE, OTCQX:CYDVF) is making progress toward becoming a key domestic supplier of battery-grade lithium carbonate, and a recent collaboration highlights the company's momentum. First Phosphate, a Canadian developer of LFP battery materials, successfully used Century Lithium’s lithium carbonate in the production of lithium iron phosphate (LFP) batteries—demonstrating real-world application of the Nevada-based company’s process. In this interview, CEO Bill Willoughby joins Proactive ...
X @Ansem
Ansem 🧸💸· 2025-07-12 12:27
RT moon (@MoonOverlord)Phantom has already onboarded nearly 3,000 new users to Hyperliquid in 1 daythis will end up as one of the most impactful partnerships of this cycle (or ever) https://t.co/Doe0Gvt2kw ...
FTRE FRAUD ALERT: Fortrea Holdings Inc. 25% Stock Drop Triggers Securities Fraud Class Action – Investors Notified to Contact BFA Law by August 1 (NASDAQ:FTRE)
GlobeNewswire News Room· 2025-07-12 11:36
Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].
斩获NASA订单的“登月新星”Firefly(FLY.US)递交IPO申请 欲登陆纳斯达克
Zhi Tong Cai Jing· 2025-07-12 04:23
Core Viewpoint - Firefly Aerospace, a Texas-based startup known for successfully landing a robotic spacecraft on the moon, has filed for an initial public offering (IPO) with the SEC, aiming to list on the Nasdaq under the ticker "FLY" [1] Group 1: Company Overview - Firefly Aerospace specializes in small to medium-sized launch vehicles, lunar landers, and orbital space tugs, targeting payloads in the 1-10 ton range and NASA's Commercial Lunar Payload Services (CLPS) missions [2][3] - The company was founded in 2014 and underwent restructuring in 2017 to focus on commercial launches and deep space cargo [2] Group 2: Recent Developments - In November of last year, Firefly completed a $175 million funding round led by RPM Ventures, achieving a valuation of over $2 billion [2] - In May of this year, Northrop Grumman, a major defense contractor, announced an investment of approximately $50 million in Firefly [2] Group 3: Competitive Landscape - Firefly Aerospace aims to create a comprehensive ecosystem of small to medium rockets, lunar cargo transport, and in-orbit tugs, positioning itself in a niche that complements NASA's and U.S. government agencies' needs rather than directly competing with SpaceX's heavy-lift capabilities [3] - The company has secured multiple CLPS contracts from NASA, with individual contract values potentially reaching hundreds of millions of dollars [2]
研判2025!中国毛细管电泳仪行业产业链、市场规模及未来前景展望:生物医药研究爆发与环境监管趋严,驱动全球毛细管电泳仪需求持续攀升[图]
Chan Ye Xin Xi Wang· 2025-07-12 02:30
内容概况:全球毛细管电泳仪行业正处于技术深化与应用拓展的关键阶段,受益于生物医药、环境监测 及食品安全等领域对高精度分析需求的增长,全球毛细管电泳仪行业规模持续扩大。2024年,全球毛细 管电泳仪市场规模为2.5亿美元,预计到2030年,其值将达到4亿美元左右。生命科学领域是核心增长引 擎。基因测序、蛋白质组学研究的爆发式增长,直接拉动了对毛细管电泳仪的需求。例如,在单细胞测 序技术普及的背景下,高灵敏度CE设备成为解析细胞异质性的关键工具。此外,生物制药行业对抗体 药物纯度检测、mRNA疫苗质量控制的严格要求,也推动了高端机型的市场渗透。环境监测与食品安全 领域的需求同样显著。全球范围内对水质污染、农药残留的监管趋严,促使毛细管电泳仪在重金属形态 分析、食品添加剂筛查等场景中的应用深化。 相关上市企业:聚光科技(300203)、 相关企业:大连日普利科技仪器有限公司、北京中成石英玻璃制品有限责任公司、上海三瑞高分子材料 股份有限公司、苏州苏纳光电有限公司、昂纳科技(深圳)集团股份有限公司、苏州汶颢芯片科技有限 公司、聚光科技(杭州)股份有限公司、苏州长光华芯光电技术股份有限公司、武汉光迅科技股份有限 公司、 ...
First Phosphate powers 100% North American batteries – ICYMI
Proactiveinvestors NA· 2025-07-11 19:58
Core Insights - First Phosphate Corp. has achieved a significant milestone in establishing a North American supply chain for lithium iron phosphate (LFP) batteries [1][5] - The company successfully produced commercial-grade LFP battery cells using 100% North American-sourced critical minerals, emphasizing domestic manufacturing independence in the energy storage sector [2][5] Company Developments - The production of LFP battery cells has been a three-year pilot project, starting with igneous phosphate rock from the company's property in Saguenay–Lac-Saint-Jean, Quebec [6] - The company plans to develop a phosphate mine by 2029, with a feasibility study currently underway [6] - The process involves producing phosphate concentrate, which is reacted with sulfuric acid to yield purified phosphoric acid, crucial for industrial applications [6] Supply Chain and Partnerships - The iron phosphate used in the batteries is sourced from the Bégin-Lamarche property, while lithium carbonate is obtained from Century Lithium in Nevada, and graphite is provided by Nouveau Monde Graphite in Quebec [7] - The company has partnered with Ultion Technologies in Nevada for the manufacturing of LFP battery cells, which are suitable for small mobility applications and can scale for large energy storage and electric vehicles [8] Future Plans - The company aims to transition from pilot to commercial scale production, with the LFP cathode plant expected to be operational by late 2026 or 2027, and the mine and phosphoric acid plant by 2029 or 2030 [8] - The goal is to produce fully North American LFP battery cells primarily from Quebec on a commercial scale by the end of the decade [8] Industry Context - The development of LFP technology originated in North America, with historical partnerships involving universities and research centers, but production shifted to China over the past two decades [9] - The recent achievement marks a reclaiming of energy storage independence for North America, showcasing the potential for domestic manufacturing using local critical minerals [9]
SynBioCon 2025第四届合成生物与绿色生物制造大会,8月宁波见!
近年来,生物制造已作为多数国家提升经济竞争力的着力点,也是我国继绿色制造、智能制造后,推进制造强国建设的又一重要抓手。同时,各地政府 地区通过结合自身优势力争实现合成生物"研发-转化-产业—集群"协同发展,发挥新质生产力 作用。 8月20-22日 将于 浙江·宁波 举 办 第四届合成生物与绿色生物制造大会 (简称: SynBioCon 2 025 ) 。大会 聚焦" 1+4 " : AI+生 物智造 这一大热门赛道; 绿色化工与新材料、 未来食品、未来农业和美妆原料四大应用领域 ,邀请国 际领先企业、代表性产业化专家、政府、园 区、资本、协会和联盟等各方共探 "十五五"生物制造产业发展趋势 ; 哪些革新技术和产品将给生物制造产业带来持续的生命力 ; 并致力于 促进科技 成果转移转化 、 产品 规模 化与人才挖掘 。 一、组织机构 主办单位: 宁波德泰中研信息科技有限公司( DT 新材料) 协办 单位: 宁波酶赛生物工程有限公司 支持单位: 中国生物工程学会生物基材料专业委员会 上海市未来产业生物制造专委会 浙江省合成生物产业技术联盟 广州合成生物产学研技术创新联盟 大会顾问: 张先恩,深圳理工大学合成生物学院 ...
Nutrien's Shares Rally 36% YTD: What's Driving the Stock?
ZACKS· 2025-07-11 13:16
Key Takeaways NTR stock has gained 35.9% year to date, outperforming its industry. High crop prices are driving strong global fertilizer demand across key markets. NTR targets $200M in cost savings by 2025 through efficiency moves.Nutrien Ltd.’s (NTR) shares have popped 35.9% year to date. The company has also outperformed the industry’s 34% rise and the S&P 500’s roughly 6.8% increase over the same period.Image Source: Zacks Investment ResearchLet’s take a look at the factors that are driving this fertil ...
Cardinal Health announces One Voice Initiative to support independent pharmacy advocacy
Prnewswire· 2025-07-11 12:30
DUBLIN, Ohio, July 11, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the launch of the Cardinal Health™ One Voice Initiative for pharmacy advocacy, which provides direct financial assistance to state pharmacy associations for the purpose of supporting independent pharmacists' advocacy efforts.  This investment furthers Cardinal Health's longstanding advocacy around the future of independent pharmacies and ongoing partnerships with industry organizations to support pharmacists' efforts to ...
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
Globenewswire· 2025-07-11 12:00
Exploring Strategic Partnerships to Expand Platform Beyond Reproductive HealthSAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 million non-dilutive funding installment under its multi-year grant agreement to support development of DARE-LARC1, the contraception-focused use case of Daré’s intelligent drug delivery system (DARE-IDDS ...